Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IL-1 Inhibition for Patients With Early Stage Triple Negative and ER-low Breast Cancer: a Window-of-opportunity Study

NCT06710197 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06710197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06710197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IL-1 Inhibition for Patients With Early Stage Triple Negative and ER-low Breast Cancer: a Window-of-opportunity Study
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Withdrawn
Start date
March 5, 2025
Completion date
February 12, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early stage triple negative er low breast cancer